Literature DB >> 27206633

Safety of total thyroid ablation in patients with Graves' orbitopathy.

M Moleti1, G Sturniolo1,2, F Vermiglio3.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27206633     DOI： 10.1007/s40618-016-0485-x

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  24 in total

Review 1.  The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.

Authors:  Luigi Bartalena
Journal:  J Clin Endocrinol Metab       Date:  2010-12-29       Impact factor: 5.958

2.  Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.

Authors:  Clementine J J van Zeijl; Eric Fliers; Chris J van Koppen; Olga V Surovtseva; Marcel E de Gooyer; Maarten P Mourits; Wilmar M Wiersinga; André M M Miltenburg; Anita Boelen
Journal:  Thyroid       Date:  2010-05       Impact factor: 6.568

Review 3.  Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.

Authors:  Mariacarla Moleti; Giuseppe Giuffrida; Giacomo Sturniolo; Giovanni Squadrito; Alfredo Campennì; Silvia Morelli; Efisio Puxeddu; Eleonora Sisti; Francesco Trimarchi; Francesco Vermiglio; Michele Marinò
Journal:  Endocrine       Date:  2016-03-22       Impact factor: 3.633

4.  Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways.

Authors:  Clementine J J van Zeijl; Eric Fliers; Chris J van Koppen; Olga V Surovtseva; Marcel E de Gooyer; Maarten P Mourits; Wilmar M Wiersinga; André M M Miltenburg; Anita Boelen
Journal:  Thyroid       Date:  2010-10-18       Impact factor: 6.568

5.  Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves' orbitopathy (GO): a prospective, randomized, single-blind clinical trial.

Authors:  Mariacarla Moleti; Maria Antonia Violi; Daniela Montanini; Costantino Trombetta; Beatrice Di Bella; Giacomo Sturniolo; Silvia Presti; Angela Alibrandi; Alfredo Campennì; Sergio Baldari; Francesco Trimarchi; Francesco Vermiglio
Journal:  J Clin Endocrinol Metab       Date:  2014-01-16       Impact factor: 5.958

6.  Increased mortality in patients with differentiated thyroid cancer associated with Graves' disease.

Authors:  Gabriella Pellegriti; Celestina Mannarino; Marco Russo; Rosa Terranova; Ilenia Marturano; Riccardo Vigneri; Antonino Belfiore
Journal:  J Clin Endocrinol Metab       Date:  2013-01-24       Impact factor: 5.958

7.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

8.  Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy.

Authors:  Mariacarla Moleti; Filiberto Mattina; Ignazio Salamone; Maria Antonia Violi; Carmelo Nucera; Sergio Baldari; Maria Grazia Lo Schiavo; Concetto Regalbuto; Francesco Trimarchi; Francesco Vermiglio
Journal:  Thyroid       Date:  2003-07       Impact factor: 6.568

9.  Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.

Authors:  M L Tanda; E Piantanida; L Liparulo; G Veronesi; A Lai; L Sassi; N Pariani; D Gallo; C Azzolini; M Ferrario; L Bartalena
Journal:  J Clin Endocrinol Metab       Date:  2013-02-13       Impact factor: 5.958

Review 10.  Extrathyroidal manifestations of Graves' disease: a 2014 update.

Authors:  Luigi Bartalena; Vahab Fatourechi
Journal:  J Endocrinol Invest       Date:  2014-06-10       Impact factor: 4.256
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.